Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Trade private companies / Buy and sell Insilico Medicine stock
Insilico Medicine

Insilico Medicine stock

Highest bid
$XXXX
x/xx/xx
Lowest ask
$XXXX
x/xx/xx
Last matched price
$XXXX
x/xx/xx
$--
Register to buy and sell private company shares
For more details on private stock price information, financing and valuation for Insilico Medicine, register or log in.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Insilico Medicine stock price

Trade metrics

Market activity 2
Limited
Active bids
XX
Active asks
XX
Highest bid price
$ XXX.XX
Lowest ask price
$ XXX.XX
Total bids
$XXX
Total asks
$XXX
Last matched price
$ XXX.XX
xx/xx/xxxx
Last matched valuation
$ XXX.XX
xx/xx/xxxx

Price history chart

7D
1M
3M
1Y
All
Forge Price
$--
Not yet available
Forge Price valuation
$--

Most active Healthcare companies

Active market

The image displayed is not current and any securities shown are for illustrative purposes only.

Forge exclusive fund offerings

Fund offerings
The image displayed is not current and any securities shown are for illustrative purposes only.
Forge exclusive fund offerings
Access high-growth companies at a fixed price—for a limited time
Invest in trending companies with lower minimums
Simplify private investing through a Forge-managed single company fund

Insilico Medicine stock FAQs

To buy and sell Insilico Medicine stock

Can you buy Insilico Medicine stock?

As Insilico Medicine is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Insilico Medicine, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Insilico Medicine stock?

To invest in a private company like Insilico Medicine through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Insilico Medicine stock?

Yes, you may sell the Insilico Medicine stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Insilico Medicine stock?

If you hold private company shares of Insilico Medicine – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Insilico Medicine on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about Insilico Medicine stock

Is Insilico Medicine a public company?

No, Insilico Medicine is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Insilico Medicine’s stock price?

Insilico Medicine is a privately held company and therefore does not have a public stock price. However, you may access Insilico Medicine private market stock price with Forge Data.

What is Insilico Medicine’s stock ticker symbol?

Insilico Medicine does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Insilico Medicine funding rounds and valuation

Total funding $--

Funding history chart

Company details

Insilico Medicine is a biotech company that utilizes generative AI with the goal of accelerating drug discovery and development. Its proprietary Pharma.AI platform aims to integrate biology, chemistry, and clinical development to efficiently advance novel drug candidates through its fully self-generated AIDD pipeline. Core values of patient focus, relentless innovation, and transparency guide Insilico Medicine's mission to revolutionize healthcare with advanced biotechnological solutions. Insilico Medicine was founded by Alex Zhavoronkov in 2014 and is headquartered in Hong Kong.
Founded
2014
Headquarters
Pak Shek Kok, Hong Kong S.A.R.
Leadership
Alexander Zhavoronkov Ph.D
Co-Founder
Alexander Aliper Ph.D
Co-Founder

Insilico Medicine investors also invested in these private compaies

Insilico Medicine news and media highlights

Chinese Investors Lead US-Based Insilico Medicine's USD100 Million-Plus Series E Round

Shanghai's Pudong Venture Capital and Hong Kong's Value Partners Group will jointly lead American biotechnology startup Insilico Medicine's Series E funding round, which is expected to exceed USD100 million.

Insilico Medicine reports preliminary data from Phase IIa IPF treatment trial

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled trial was conducted across 21 sites in China, enrolling 71 patients with IPF. It assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12-week oral ISM001-055.

Hong Kong-based biotech Insilico Medicine shifts IPO plan to city from New York

Hong Kong-based biotech company Insilico Medicine has set its sights on an initial public offering in the city, shelving its earlier New York fundraising plan, as the start-up seeks capital to finance clinical trials of drugs discovered and designed by artificial intelligence. While details such as the IPO timetable or the amount have not been disclosed, the company in an exchange filing on Tuesday named Morgan Stanley, China International Capital Corporation and BNP Paribas Securities Asia as its overall coordinators.

The first fully A.I.-generated drug enters clinical trials in human patients

The first drug fully generated by artificial intelligence entered clinical trials with human patients this week. Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug, INS018_055, as a treatment for idiopathic pulmonary fibrosis, a chronic disease that causes scarring in the lungs. The condition, which has increased in prevalence in recent decades, currently affects about 100,000 people in the U.S. and can lead to death within two to five years if untreated, according to the National Institutes of Health.
Browse More Insights

Other companies like Insilico Medicine in the Healthcare Software sector

Sector: Healthcare
Subsector: Healthcare Software
Trade Metrics Last Funding Round
Company Forge Price Last Matched Price Share Class Post-Money Valuation 3 Price Per Share Amount Raised
AKASAAKASA--$xx.xxSeries C$977.06MM$35.30$120MM
AbridgeAbridge--$xx.xxSeries E$5.3B$158.48$300MM
AkidoAkido--$xx.xxSeries B$373.15MM$13.45$60MM
BenchlingBenchling--$xx.xxSeries F$6.1B$32.70$95MM
Hippocratic AIHippocratic AI--$xx.xxSeries B$1.64B$13.42$141MM
InnovaccerInnovaccer$3.29 -$0.21 (6.00%)$xx.xxSeries F-1$3.45B$7.39$153.04MM
OpenEvidenceOpenEvidence--$xx.xxSeries B-1$3.5B$150.87$30MM
Rad AIRad AI--$xx.xxSeries C$527.53MM$22.51$80.9MM
SukiSuki--$xx.xxSeries D$283.39MM$4.59$50MM
Viz.aiViz.ai--$xx.xxSeries D$1.28B$6.35$120MM

Forge is your trusted partner to buy and sell Insilico Medicine stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jul 15, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Most active companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.